Network pharmacological analysis showed that the key targets of SJT in the treating RA probably were STAT3, AKT1, JUN, HSP90AA1, TNF, and the potential mechanism would be associated with modulation on PI3K-Akt, MAPK, Ras, AGE-RAGE, HIF-1, TNF, chemokine, IL-17, FoxO, Rap 1 signaling pathways. Here, IL17A is linked to rheumatoid arthritis.